Hubei Goto BiopharmLtd Valuation

Is 300966 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300966 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300966 (CN¥17.62) is trading above our estimate of fair value (CN¥0.32)

Significantly Below Fair Value: 300966 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300966?

Key metric: As 300966 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 300966. This is calculated by dividing 300966's market cap by their current revenue.
What is 300966's PS Ratio?
PS Ratio	3.7x
Sales	CN¥546.75m
Market Cap	CN¥2.16b

300966 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.7x
Enterprise Value/EBITDA	260.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 300966's PS Ratio compare to its peers?

The above table shows the PS ratio for 300966 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.6x
688163 Shanghai Serum Bio-Technology	10.3x	n/a	CN¥2.0b
300313 Xinjiang Tianshan Animal Husbandry Bio-engineering	13.7x	n/a	CN¥2.0b
603716 Thalys Medical Technology Group	0.8x	n/a	CN¥1.5b
300683 Wuhan Hiteck Biological PharmaLtd	5.7x	n/a	CN¥3.5b
300966 Hubei Goto BiopharmLtd	3.7x	n/a	CN¥2.0b

Price-To-Sales vs Peers: 300966 is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (7.6x).

Price to Sales Ratio vs Industry

How does 300966's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
603716 Thalys Medical Technology Group	0.8x	n/a	US$211.83m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 300966 is good value based on its Price-To-Sales Ratio (3.7x) compared to the CN Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is 300966's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300966 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 300966's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥50.2b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.49

-2.1%

7.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.25

-1.7%

16.8%